These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 7906947)

  • 1. Clinical studies in Alzheimer patients with positron emission tomography.
    Nordberg A
    Behav Brain Res; 1993 Nov; 57(2):215-24. PubMed ID: 7906947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography.
    Nordberg A; Lilja A; Lundqvist H; Hartvig P; Amberla K; Viitanen M; Warpman U; Johansson M; Hellström-Lindahl E; Bjurling P
    Neurobiol Aging; 1992; 13(6):747-58. PubMed ID: 1491741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET studies and cholinergic therapy in Alzheimer's disease.
    Nordberg A
    Rev Neurol (Paris); 1999; 155 Suppl 4():S53-63. PubMed ID: 10637939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo detection of neurotransmitter changes in Alzheimer's disease.
    Nordberg A
    Ann N Y Acad Sci; 1993 Sep; 695():27-33. PubMed ID: 7902055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: effect of tacrine treatment.
    Nordberg A; Lundqvist H; Hartvig P; Andersson J; Johansson M; Hellstrŏm-Lindahi E; Långström B
    Dement Geriatr Cogn Disord; 1997; 8(2):78-84. PubMed ID: 9065319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of long-term treatment with tacrine (THA) in Alzheimer's disease as visualized by PET.
    Nordberg A
    Acta Neurol Scand Suppl; 1993; 149():62-5. PubMed ID: 8128843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetic analysis of regional (S)(-)11C-nicotine binding in normal and Alzheimer brains--in vivo assessment using positron emission tomography.
    Nordberg A; Lundqvist H; Hartvig P; Lilja A; Långström B
    Alzheimer Dis Assoc Disord; 1995; 9(1):21-7. PubMed ID: 7605618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease.
    Kadir A; Almkvist O; Wall A; Långström B; Nordberg A
    Psychopharmacology (Berl); 2006 Nov; 188(4):509-20. PubMed ID: 16832659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET.
    Kadir A; Darreh-Shori T; Almkvist O; Wall A; Långström B; Nordberg A
    Psychopharmacology (Berl); 2007 May; 191(4):1005-14. PubMed ID: 17310387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of PET in dementia disorders.
    Nordberg A
    Acta Neurol Scand Suppl; 1996; 168():71-6. PubMed ID: 8997424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroreceptor changes in Alzheimer disease.
    Nordberg A
    Cerebrovasc Brain Metab Rev; 1992; 4(4):303-28. PubMed ID: 1486017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nerve growth factor affects 11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (case report).
    Olson L; Nordberg A; von Holst H; Bäckman L; Ebendal T; Alafuzoff I; Amberla K; Hartvig P; Herlitz A; Lilja A
    J Neural Transm Park Dis Dement Sect; 1992; 4(1):79-95. PubMed ID: 1540306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term tacrine treatment in three mild Alzheimer patients: effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG, and cognitive abilities.
    Nordberg A; Amberla K; Shigeta M; Lundqvist H; Viitanen M; Hellström-Lindahl E; Johansson M; Andersson J; Hartvig P; Lilja A; Långström B; Winblad B
    Alzheimer Dis Assoc Disord; 1998 Sep; 12(3):228-37. PubMed ID: 9772028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of FDG PET and IQNB SPECT in normal subjects and in patients with dementia.
    Weinberger DR; Jones D; Reba RC; Mann U; Coppola R; Gibson R; Gorey J; Braun A; Chase TN
    J Neuropsychiatry Clin Neurosci; 1992; 4(3):239-48. PubMed ID: 1498576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebral muscarinic acetylcholinergic receptor measurement in Alzheimer's disease patients on 11C-N-methyl-4-piperidyl benzilate--comparison with cerebral blood flow and cerebral glucose metabolism.
    Yoshida T; Kuwabara Y; Ichiya Y; Sasaki M; Fukumura T; Ichimiya A; Takita M; Ogomori K; Masuda K
    Ann Nucl Med; 1998 Feb; 12(1):35-42. PubMed ID: 9559960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positron emission tomography imaging in dementia.
    Herholz K; Carter SF; Jones M
    Br J Radiol; 2007 Dec; 80 Spec No 2():S160-7. PubMed ID: 18445746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Alzheimer's disease imaging agents for clinical studies.
    Ryu EK; Chen X
    Front Biosci; 2008 Jan; 13():777-89. PubMed ID: 17981587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of positron emission tomography imaging in understanding Alzheimer's disease.
    Barthel H; Seibyl J; Sabri O
    Expert Rev Neurother; 2015 Apr; 15(4):395-406. PubMed ID: 25752209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HMPAO SPET and FDG PET in Alzheimer's disease and vascular dementia: comparison of perfusion and metabolic pattern.
    Mielke R; Pietrzyk U; Jacobs A; Fink GR; Ichimiya A; Kessler J; Herholz K; Heiss WD
    Eur J Nucl Med; 1994 Oct; 21(10):1052-60. PubMed ID: 7828614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioligand imaging of α4β2* nicotinic acetylcholine receptors in Alzheimer's disease and Parkinson's disease.
    Meyer PM; Tiepolt S; Barthel H; Hesse S; Sabri O
    Q J Nucl Med Mol Imaging; 2014 Dec; 58(4):376-86. PubMed ID: 25387119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.